Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (160)
  2. Journal Article (105)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (119)
  5. Department of Pathology and Laboratory Medicine (102)
  6. Human Oncology and Pathogenesis Program (100)

More Groups

People
  1. Gregory Riely (107)
  2. Mark Kris (94)
  3. Marc Ladanyi (71)
  4. Charles Rudin (57)
  5. Maria Arcila (55)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (14)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Journal of Thoracic Oncology (62)
  3. Annals of Oncology (26)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (84)
  2. American Society of Clinical Oncology (82)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (30)
  5. Nature Publishing Group (11)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (285)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of the KRAS/EGFR mutation profile and survival of "collegiate smokers" and never smokers with advanced lung cancers
    Meeting Abstract

    Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Janjigian, Y. Y.; Drilon, A. E. D.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)
    Meeting Abstract

    Johnson, M. L.; Yu, H. A.; Hart, E. M.; Worden, R.; Rademaker, A.; Gupta, R.; Miller, C.; Patel, J. D.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Who should receive EGFR tyrosine-kinase inhibitors?
    Journal Article

    Yu, H. A.; Riely, G. J.
    Lancet Oncology (2012)

    Fulltext@MSK | Save